Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced Stage Non-Small Cell Lung Cancer Posted on February 27, 2023February 27, 2023, in News, Press Releases Read more
Grid Therapeutics Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting Posted on November 8, 2022, in Press Releases Read more
2022 Distinguished Service Awards Presented Posted on August 8, 2022, in News, Press Releases Read more
Homegrown Immunotherapy Trialed in Lung Cancer Posted on December 16, 2020December 16, 2020, in News, Press Releases Read more
Tumour extracellular vesicle‐derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement‐dependent cytotoxicity of tumour cells Posted on November 30, 2020, in News, Press Releases Read more
Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients Posted on June 24, 2020, in News, Press Releases Read more
Grid Therapeutics Announces FDA Approval of IND Application for GT103 Posted on April 15, 2020, in News, Press Releases Read more
Human antibody enhances medication and significantly increases the death of cancer cells Posted on July 3, 2017August 3, 2017, in News, Press Releases Read more
Human antibody bolsters cancer drug performance Posted on July 1, 2017August 3, 2017, in News, Press Releases Read more
New antibody appears to re-activate immune system in cancer therapy Posted on June 28, 2017August 3, 2017, in News, Press Releases Read more
